Antipsychotic drugs double risk of death among Alzheimer's patients

January 9, 2009

New research into the effects of antipsychotic drugs commonly prescribed to Alzheimer's patients concludes that the medication nearly doubles risk of death over three years. The study, funded by the Alzheimer's Research Trust, was led by Prof Clive Ballard's King's College London team and is published in Lancet Neurology on 9 January.

The study involved 165 Alzheimer's patients in UK care homes who were being prescribed antipsychotics. 83 continued treatment and the remaining 82 had it withdrawn and were instead given oral placebos.

Findings showed a significant increase in risk of death for patients who continued taking antipsychotic medication. The difference between the two groups became more pronounced over time, with 24-month survival rates for antipsychotic-treated patients falling to 46% versus 71% on the placebo and at 36 months it was 30% versus 59%. It means that after three years, less than a third of people on antipsychotics were alive compared to nearly two thirds using the dummy drug.

Antipsychotics are used to treat symptoms of agitation, delusions and aggressive behaviour. NICE guidelines recommend that the drugs should only be used for short periods of time and where symptoms are severe, and should be very carefully monitored, although in clinical practice the average length of prescription is 1-2 years. While there is evidence of modest short-term (6-12 weeks) benefits of antipsychotic treatment for the serious behavioural symptoms of Alzheimer's, a previous Alzheimer's Research Trust study showed that these benefits were not evident over longer periods of treatment.

As many as 100,000 people with dementia are routinely prescribed antipsychotics in UK care homes. It could mean 23,500 people dying prematurely, according to a 2008 report by Paul Burstow MP.

Prof Clive Ballard of King's College London said:
"The results further highlight the need to seek less harmful alternatives for the long-term treatment of behavioural symptoms in Alzheimer's patients. At the moment, there is still a limited place for antipsychotics in the treatment of Alzheimer's, particularly severe aggression, but the serious concerns of the drugs shown by our research emphasise the urgent need to put an end to unnecessary and prolonged prescribing".

Rebecca Wood, Chief Executive of the Alzheimer's Research Trust, said:
"The findings of this research are a real wake-up call and underline the danger of prescribing antipsychotics long-term for anything other than exceptional circumstances. We must avoid the use of these drugs as a potentially dangerous 'chemical cosh' to patients who would be better off without it. The study also highlights the urgent need to develop better treatments as Alzheimer's patients have few options available to them.

"700,000 people in the UK have dementia; we urgently need to fund more research to develop the new treatments we so desperately need".

Source: Alzheimer's Research Trust

Explore further: A tumor that can unroll: Engineers create new technology for understanding cancer growth

Related Stories

Nanocarriers may carry new hope for brain cancer therapy

November 19, 2015

Glioblastoma multiforme, a cancer of the brain also known as "octopus tumors" because of the manner in which the cancer cells extend their tendrils into surrounding tissue, is virtually inoperable, resistant to therapies, ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jan 09, 2009
Another example of the triumph of commercial drug companies pushing their wares beyond their proven scientific value. Its more profitable to sell drugs than to extend lives without drugs.
not rated yet Jan 09, 2009
again, it would be better if these articles included spcific drugs that were studied. Even some of them would be better than none. 'antipsychotics' gives us a hint but thats all. for example, is Aricept considered an antipsychotic? wth is this info almost always left out?
not rated yet Jan 09, 2009
and isnt it great the way many medical journals charge extravagantly for the articles? that way they can be sure the info isnt available to just anyone. nice going!
5 / 5 (1) Jan 09, 2009
My Dad died of Alzheimer's - his life before the drugs was one of spitting, yelling and pushing. He pushed his aide off a bus and almost killed her. The only thing that calmed him was one of these "deadly" anti-psychotic drugs. The advertising for Alzheimers drugs always show a gentle old man or woman, docile and smiling. That's just not the way it is folks. The behaviors are what is most terrible and terrifying. Spitting, hitting, pushing, choking, yelling foul names at family, Did my father die earlier because of these drugs - maybe. Did he have any quality of life if he didn't take them - no. It's a terrible, exhausting disease and it affects the individual and everyone around them and it only gets worse with time.
not rated yet Jan 10, 2009
thank you marushka for that personal perspective on this terrible disease.
not rated yet Jan 12, 2009
Marushka is so right about this - it's all about context and quality. Without these "deadly" drugs, my mother-in-law's day-to-day existence would involve extreme distress caused by the paranoia, hallucinations, aggression and delusions that accompany her dementia. This disease is progressive and only ever gets worse - what do people want, a prolonged existence in a psychological hades or a little less time on the planet coupled with some semblance of comfort.
Big deal - by the time most dementia sufferers need this kind of medication, longevity is pretty low down on the list of requirements. It's all about quality.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.